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Abstract
Background: Hepatitis C can lead to liver fibrosis and cirrhosis. We compared readily available non-invasive fibrosis
indexes for the fibrosis progression discrimination to find a better combination of existing non-invasive markers.
Methods: We studied 157 HCV infected patients who underwent liver biopsy. In order to differentiate HCV fibrosis
progression, readily available AAR, APRI, FI and FIB-4 serum indexes were tested in the patients. We derived a new
fibrosis-cirrhosis index (FCI) comprised of ALP, bilirubin, serum albumin and platelet count. FCI = [(ALP × Bilirubin) /
(Albumin × Platelet count)].
Results: Already established serum indexes AAR, APRI, FI and FIB-4 were able to stage liver fibrosis with correlation
coefficient indexes 0.130, 0.444, 0.578 and 0.494, respectively. Our new fibrosis cirrhosis index FCI significantly
correlated with the histological fibrosis stages F0-F1, F2-F3 and F4 (r = 0.818, p < 0.05) with AUROCs 0.932 and
0.996, respectively. The sensitivity and PPV of FCI at a cutoff value < 0.130 for predicting fibrosis stage F0-F1 was
81% and 82%, respectively with AUROC 0.932. Corresponding value of FCI at a cutoff value ≥1.25 for the prediction
of cirrhosis was 86% and 100%.
Conclusions: The fibrosis-cirrhosis index (FCI) accurately predicted fibrosis stages in HCV infected patients and
seems more efficient than frequently used serum indexes.
Background
Hepatitis C virus (HCV) is considered as a major basis
of liver associated diseases throughout the world. More
than 350 million people (3% of the world’s populations)
[1,2] and almost 10 million people in Pakistan are
infected with HCV [3]. The genotypes 3a, 3b, 1a and 4a
are most prevalent in Pakistan [4]. It is predicted that
hepatocellular carcinoma (HCC) develops in 1-4% of
HCV infected patients in the first five years following
the onset of cirrhosis, but cirrhosis may occur with in
the range of 10-50 years [5]. In HCV infected patients,
liver biopsy is considered essential to stage liver fibrosis.
Procedure of liver biopsy is invasive, expensive and not
suitable for all patients. Patients can have severe side
effects like pain andharsh complications also leading to
death [[1,3] and [5]]. Many previous studies reported
that host factors reflect fibrosis development leading to
HCC [6,7], so these can be used as non-invasive means
to overcome the weaknesses arise from biopsy proce-
dures. Chronic hepatitis C is known as hepatic lesions
associated with increased levels of aminotransferases
more than 6 months. Moreover, treatment with inter-
feron therapy should be based on the liver fibrosis stage
[8]. Various authors tried to find accurate non-invasive
markers and develop correlations between the serum
aminotransferases levels, hyluronic acid level, collagen
level, platelet count and HCV viral titer with fibrosis
stages but no clear conclusions were formed. Several
scoring systems like AST to ALT ratio (AAR), AST-Pla-
telet ratio (APRI), Fibrotest (FT), Fibrosis Index (FI) and
FIB-4 with different thresholds to predict presence or
absence of fibrosis or cirrhosis in patients infected with
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end stage cirrhosis cannot be predicted accurately using
a single system [9-18].
In this study, we compared and evaluated diagnostic
accuracy of the readily available non-invasive serum
indexes including AAR, APRI, FI and FIB-4 to find
accurate and reliable non-invasive markers for evaluat-
ing fibrosis progression. We also developed a new
non-invasive serum marker index for this purpose by
evaluating several clinic-pathological features. A mar-
ker with high predictive values would eliminate the
need of liver biopsy that also reduces the cost and
risks associated to it.
Methods
Patients
This study was conducted at the Department of Pathol-
ogy, Jinnah Hospital, Lahore; Mayo Hospital, Lahore
and Liver Centre, Faisalabad in collaboration with
Applied and Functional Genomics Lab, National Centre
of Excellence in Molecular Biology (CEMB), University
of the Punjab, Lahore, Pakistan. HCV RNA-positive
patients were identified among HCV antibody (anti-
HCV) positive patients. Later, the study plan was dis-
cussed with patients and the biopsy was taken only from
those patients who were willing for this procedure. The
purpose of this study was to design a new Index so that
disease progression can be evaluated non-invasively and
future need of biopsy can be eliminated. This was a ret-
rospective cross-sectional study. This analytical study
was carried out from March 2008 to September 2010.
Patients who received a previous course of INF or
immunosuppressive therapy or who had clinical evi-
dence of HBV or HIV and any type of liver cancer were
excluded from the study. Patients who refused to have a
liver biopsy or for whom it was contraindicated, i.e.,
because of a low platelet count, prolonged prothrombin
time or decompensated cirrhosis were also excluded
from the study. The liver biopsy procedure, its advan-
tages and possible adverse effects were explained to the
patients. Informed consent were obtained from patients
contained information about demographic data, possible
transmission route of HCV infection, clinical, virological
and biochemical data. This study included 157 patients
(M/F 114/43; mean age 38.1 ± 10.2, age range 19-58
years). The study was approved by Institutional Review
Board (IRB, CEMB). The Federal-wide Assurance docu-
ment (ID: FWA00001758) was approved by the local
office for Human Research Protection.
Histological evaluation of biopsy samples
The histological evaluation of paraffin-embedded liver
specimens was carried out at the Pathology Department,
Jinnah Hospital, Lahore, according to METAVIR scoring
system [19]. Liver biopsies were evaluated by two inde-
pendent pathologists without prior information to
patient’s history. Histological staging based on the
degree of fibrosis have five degrees of fibrosis: as F0 (no
fibrosis), F1 (mild fibrosis without septa), F2 (moderate
fibrosis with few septa), F3 (severe fibrosis with numer-
ous septa without cirrhosis) and F4 (cirrhosis). We
further grouped fibrosis stages as F0-F1 (minimal fibro-
sis), F2-F3 (advanced fibrosis), F4 (cirrhosis) and F2-F4
(significant fibrosis).
HCV RNA detection and quantitative PCR
RNA was extracted from 140 μl serum samples using
QIAamp viral RNA extraction kit (Qiagen USA cat #
52906) according to the manufacturer’s protocol. cDNA
was synthesized using Moloney murine leukemia virus
(MmLV) reverse transcriptase (Invitrogen, USA). First
round and nested PCRs were carried out with Taq Poly-
merase (Fermentas USA) and analyzed on 2% agarose
gel. Qiagen HCV quantitative kit was used to perform
HCV RNA quantification with 10 ul of the extracted
RNA on Roche Real Time PCR using fluorescent probes
to detect amplification after each replicating cycle.
HCV genotyping
HCV genotyping was carried out using Invader HCV
genotyping assay (Third wave technology USA). Briefly,
about 100 ng of the HCV RNA was reverse transcribed
to cDNA using 200U of MmLV (Invitrogen, USA).
From the amplified product, 2 μl was taken and the gen-
otyping assay was performed for 12 different HCV types.
Comparison of already available non-invasive serum
biomarkers to evaluate patient’s liver biopsy data
Serum samples and liver specimens collected from each
patient were stored at -70°C for further biochemical
analysis. The routine liver function tests (LFTs), Hb,
serum albumin and direct bilirubin levels were antici-
pated for each patient. All biochemical tests and their
scores were made without knowledge of liver biopsy
results and all patients were evaluated for AAR, APRI,
Fibrosis Index (FI) and FIB-4 indexes.
The following formulas were used to review the pre-
dicted scores with the particular cut-off values as men-
tioned previously.
￿ AAR [15] = AST (IU/l)/ ALT (IU/l)
If AST/ALT ≥ 1, significant cirrhosis
￿ APRI [16] = [{AST (IU/l)/ ALT_ULN (IU/l)}×
100]/ platelet count (10
9/l)
If APRI < 0.5, no or minimal fibrosis; if APRI >
1.5, significant fibrosis
￿ FI [ 1 7 ]=8 . 0-0 . 0 1×P L T( 1 0
9/l) - serum albumin
(g/dl)
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≥ 2.1, significant fibrosis, and if F-Index ≥ 3.3,
significant cirrhosis
￿ FIB-4 [18] = [Age (Years) × AST (IU/l)]/[Platelet
count (× 10
9/l) × ALT (IU/l)1/2]
If FIB-4 < 1.45, no or minimal fibrosis, If FIB-4 >
3.25, significant fibrosis
Statistical analysis
The data was analyzed using statistical package SPSS
version 16 for windows. A p v a l u eo f0 . 0 5w a sc o n s i d -
ered statistically significant. All data was presented as
mean values or no. of patients. Spearman’s rank correla-
tion was used to assess the significant association
between continuous variables and liver fibrosis stages.
The student t-test was used to compare arithmetic
means and parameters while Chi-square (X2) test was
used to compare categorical data, correlation with Fish-
er’s exact test was used when appropriate. Patients were
divided into three main groups as, patients with no or
minimal fibrosis (F0-F1), patients with significant fibro-
sis (F2-F3) and patients with clinically significant cirrho-
sis (F4). The independently distinguished values of
biochemical markers and AAR, APRI, FIB-4 and FI
indexes for the prediction of significant fibrosis and cir-
rhosis were evaluated using univariate and multiple
regression analysis. Area under the receiver operating
characteristic (ROC) curves (AUROCs) was used to
compare and deduce the diagnostic accuracies of the
selected bio-markers.
Results
Patient’s data
The demographic and clinical outcomes of the 157
HCV infected patients are briefly explained in Table 1.
The evaluation of chronic HCV activity (inflammatory
grade) showed mild chronic hepatitis in 51 patients,
moderate chronic hepatitis in 67 patients and severe
chronic hepatitis in 39 patients. The determination of
liver fibrosis showed stage F0 in 29, F1 in 39, 34
patients in F2 and F3 stage each and 21 patients in F4
or advanced fibrosis leading to cirrhosis. Our data
s h o w e dt h ep r e s e n c eo fg e n o t y p e1 ai n2 2a n d3 ai n
135 patients, 95 patients were < 40 years of age, while
62 were > 40 years of age.
Relationship between clinical findings and fibrosis
Liver fibrosis stages were statistically significant between
age groups (p< 0.05). Mild and moderate fibrosis was
diagnosed mostly in younger patients while more
advanced stages were observed in patients over 40 years
old. Patients with F0 fibrosis were too young as com-
pared to those who developed moderate or severe
fibrosis leading to cirrhosis (Mean age ± SD, 25.9 ± 2.4
years). The distribution of liver fibrosis stages with
regard to gender and genotypes of patients illustrated in
Table 2 showed no significant differences (for gender:
p = 0.247 and for genotypes: p = 0.258). Univariate ana-
lysis revealed that serum viral loads, bilirubin, albumin,
platelet count, AST and ALP levels were significantly
different in various fibrosis stages (Table 2).
Diagnosis of fibrosis using already available AAR, APRI, F-
Index, and FIB-4 serum indexes
The relationship between the fibrosis stages and four
serum indexes: AAR, APRI, FI and FIB-4 is illustrated in
Figure 1 (see also Table 2). There was a significant rela-
tionship between fibrosis stages and serum indexes
except AAR (p > 0.05). A gradual increase in the level
of APRI, FI and FIB-4 indexes was observed in fibrosis
stages.
The AUROCs of the serum non-invasive indexes
scores are shown in Table 3. AUROC of FI was higher
than APRI (p< 0.05) for differentiating minimal fibrosis
from significant fibrosis (Figure 2). To predict cirrhosis,
FI showed high AUROC than AAR. Spearman correla-
tion between each serum index score and fibrosis stages
was high for F-Index, FIB-4 and APRI, while, AAR
showed significantly low ‘r’ index indicated in Table 3.
Table 1 Demographic, clinical, and liver histological
features of 157 chronic HCV infected patients
Features Mean (± SD) Minimum Maximum
Sex (Male/Female) 114/43 - -
Age (years) 38.1 ± 10.2 19 58
Age groups (< 40/ > 40) 95/62 - -
Genotype (1a/3a) 22/135 - -
Viral load (IU/ml) 5.47 × 10
7 ± 1.4
×1 0
8
1.7 × 10
4 1.01 × 10
9
Hb level (g/dl) 12.7 ± 1.3 10.3 16.7
Bilirubin (mg/dl) 1.03 ± 0.36 0.5 2.1
ALT (IU/l) 134.4 ± 63.1 18 271
ALP (IU/l) 147.7 ± 101.5 20 438
AST (IU/l) 106.7 ± 68.2 20 395
Serum Albumin (g/dl) 4.1 ± 0.31 3.1 4.9
Platelet count (× 10
9/l) 154.5 ± 41.7 49 229
Liver fibrosis stages, n (%)
F0 (n = 29, 18.5%) - -
F1 (n = 39, 24.8%) - -
F0+F1 (minimal fibrosis) (n = 68, 43.3%) - -
F2 (n = 34, 21.7%) - -
F3 (n = 34, 21.7%) - -
F2+F3 (advanced fibrosis) (n = 68, 43.3%) - -
F4 (Cirrhosis) (n = 21, 13.4%) - -
F2+F3+F4 (significant
fibrosis)
(n = 89, 56.7%) - -
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analyzed the sensitivity and specificity of each index for
significant fibrosis and cirrhosis. Patients with minimal
fibrosis can be identified from advanced/significant or
cirrhotic patients using FIB-4, AAR, APRI and F-Index
with sensitivity 51%, 67.6%, 19.1% and 100% and specifi-
city 85.4%, 42.8%, 97.7% and 58.4%, respectively. At a
c u t - o f fv a l u e>3 . 2 5f o rF I B - 4 ,>1 . 5f o rA P R I ,>1f o r
AAR and > 3.3 for F-Index have 59.2%, 34.8%, 42.8%
and 38.1% sensitivity and 82.3%, 67.6%, 67.6% and 100%
specificity, respectively, to discriminate advanced fibrosis
stages from minimal.
Diagnosis of fibrosis with clinic-pathological features
including viral load, Hb level, bilirubin, ALT, ALP, AST,
albumin and platelet count
Viral load was significant among fibrosis stages. It gra-
dually increased in advanced fibrosis, and then suddenly
dropped in cirrhosis. ALT and Hb levels were not signif-
icant, while AST levels were noteworthy to differentiate
liver fibrosis stages. Meanwhile, only 16 (10.1%) and 21
(13.3%) patients showed normal ALT and AST levels,
respectively, independent of fibrosis stage. The discrimi-
native values of the biochemical markers for the predic-
tion of different fibrosis stages were determined by
logistic regression analysis. By univariate analysis (p <
0.05, Table 2), viral load, bilirubin, ALP, AST, albumin
and platelet count were significantly associated with var-
ious fibrosis stages. However, in multivariate analysis,
bilirubin, ALP, albumin and platelet count were found
to be independently predictive (Table 4). This informa-
tion related to these biochemical markers can also be
helpful in differentiating liver fibrosis stages. Figure 3
shows the box plot of these four markers with liver his-
tological stages. It is clear from Figure 3 and Table 2
that as the fibrosis increased, bilirubin and serum ALP
level also increased, while platelet count and albumin
level gradually reduced in cirrhosis. It was interesting to
note that serum ALP and bilirubin was 2 times and 5
times higher in cirrhotic patients, respectively, than nor-
mal limits.
Based on ROC curve analysis as illustrated in Figure 4,
four significant serum markers ALP, bilirubin, albumin
and platelet count showed superior diagnostic power
with high AUROCs for differentiating various fibrotic
stages and cirrhosis as given in Table 5. Our data
showed that if these four serum markers ALP, bilirubin,
Table 2 Distribution of each variable according to fibrosis stages
Factor F0 (n = 29) F1(n = 39) F2(n = 34) F3(n = 34) F4(n = 21) P value
Age 25.9 ± 2.4 37.9 ± 9.5 42.8 ± 7.6 37.7 ± 8.5 48.4 ± 7.1 < 0.05
Sex (M/F) 19/10 35/4 26/8 20/14 14/7 0.247
Genotype (1a/3a) 8/21 4/35 3/31 3/31 4/17 0.258
HAI score 3.8 ± 2.1 6.05 ± 2.8 6.8 ± 3.2 6.9 ± 4.02 7.6 ± 2.9 < 0.05
Viral load 6.2 × 10
5 ± 1.2 × 10
6 1.3 ± × 10
7 ± 1.5 × 10
7 2.1 × 10
8 ± 2.4 × 10
8 2.4 × 10
7 ± 2.5 × 10
7 2.9 × 10
5 ± 2.9 × 10
5 < 0.05
Hb level 12.8 ± 1.3 12.6 ± 1.2 12.77 ± 1.7 12.9 ± 1.3 12.3 ± 1.2 0.328
Bilirubin 0.7 ± 0.1 0.88 ± 0.2 0.99 ± 0.27 1.2 ± 0.3 1.62 ± 0.31 < 0.05
ALT 120.2 ± 71.9 117.8 ± 55.3 152.1 ± 66.5 139.6 ± 56.6 147.5 ± 61.2 0.091
ALP 72.6 ± 16.8 88.1 ± 47.5 110.7 ± 45.1 208.6 ± 75.9 323.8 ± 80.1 < 0.05
AST 83.1 ± 57.9 107.1 ± 66.5 95.9 ± 51.4 106.9 ± 65.4 155.5 ± 90.6 < 0.05
Albumin 4.5 ± 0.1 4.3 ± 0.16 4.2 ± 0.18 4.08 ± 0.2 3.6 ± 0.33 < 0.05
Platelet count 191.3 ± 18.7 185.1 ± 21.2 162.1 ± 16.6 125.5 ± 18.7 81.6 ± 17.7 < 0.05
AAR 0.8 ± 0.58 1.14 ± 1.21 0.93 ± 1.1 1.02 ± 1.03 1.26 ± 0.95 0.522
APRI 1.04 ± 0.75 1.39 ± 0.87 1.40 ± 0.75 2.09 ± 1.33 4.7 ± 3.1 < 0.05
FI 1.24 ± 0.26 1.51 ± 0.28 1.81 ± 0.27 2.33 ± 0.28 3.2 ± 0.4 < 0.05
FIB-4 1.21 ± 0.95 2.17 ± 1.47 2.31 ± 1.57 3.06 ± 2.1 8.73 ± 6.59 < 0.05
Figure 1 Box plots of the AAR, APRI, FIB-4 and FI for different
fibrosis stages. The horizontal line inside each box represents the
median, while the top and bottom of boxes represent the 25
th and
75
th percentiles, respectively. Vertical lines from the ends of the box
encompass the extreme data points.
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they have high PPV and NPV for predicting cirrhosis
and differentiating no/minimal fibrosis from significant
fibrosis.
For the detection of significant cirrhosis, platelet count
less than 100 showed 81% sensitivity, 98% specificity,
89% PPV and 97% NPV. For the same outcome, ALP >
240 IU/l had sensitivity, specificity, PPV and NPV of
90%, 92%, 60.7% and 97%, respectively. The bilirubin
and albumin were also quite sensitive for the presence
of cirrhosis. Bilirubin level > 1.5 had a sensitivity 66.6%,
specificity 95.5%, PPV 70% and NPV 94%, while albumin
< 3.85 g/dl has sensitivity, specificity, PPV and NPV
71.4%, 93%, 60% and 95%, respectively.
In no/minimal fibrosis, ALP < 120 IU/l showed sensi-
tivity, specificity, PPV and NPV 85%, 70%, 68% and 86%,
respectively. At cut-off value > 150, platelet count also
showed high sensitivity (98%) and specificity (70%) with
71.2% PPV and 98% NPV. Serum bilirubin and albumin
also showed same pattern with high sensitivity, specifi-
city, PPV and NPV as shown in Table 5.
Construction of a new Index for the prediction of fibrosis
stage
Based on the relationship of the regression coefficients
of four-biochemical markers, ALP, bilirubin, albumin
and platelet count, we developed a new fibrosis-cirrhosis
index for the prediction of HCV disease progression
from initial fibrosis stage to end stage cirrhosis.
Table 3 Validity of serum AAR, APRI, FIB-4 and FI in 157 HCV infected patients
AAR
Cutoff value Spe% Sen% PPV% NPV% F0-F3 (n = 136 ) F4 (n = 21) AUC [95% CI]
< 1 42.8 67.6 88.4 16.9 92/44 12/9 0.468[0.377-0.559]
> 1 67.6 42.8 16.9 88.4 44/92 9/12 0.610[0.483-0.738]
APRI
Cutoff value Spe% Sen% PPV% NPV% F0-F1 (n = 68) F2-F4 (n = 89) AUC [95% CI]
< 0.5 97.7 19.1 86.6 61.2 13/55 2/87 0.715[0.635-0.795]
> 1.5 67.6 34.8 58.4 44.2 22/46 31/58 0.876[0.782-0.971]
FIB-4
Cutoff value Spe% Sen% PPV% NPV% F0-F2 (n = 102) F3-F4 (n = 55 ) AUC [95% CI]
< 1.45 85.4 51 86.6 48.4 52/50 8/47 0.732 [0.655-0.809]
> 3.25 82.3 59.2 64 79.2 18/84 33/22 0.545[0.456-0.635]
FI
Cutoff value Spe% Sen% PPV% NPV% F0-F1 (n = 68) F2-F4 (n = 89) AUC [95% CI]
< 2.1 58.4 100 64.7 100 68/0 37/52 0.939[0.903-0.974]
Cutoff value Spe% Sen% PPV% NPV% F0-F3 (n = 136) F4 (n = 21) AUC [95% CI]
> 3.3 100 38.1 100 91.2 0/136 8/13 0.990[0.979-1.001]
Spearman rank correlation coefficient (R-index) for AAR = 0.130, APRI = 0.444, FIB-4 = 0.494 and FI = 0.578
Figure 2 Receiver operating characteristic curves generated by
four serum markers, AAR, APRI, FIB-4 and FI for differentiation
between patients in fibrosis stage F0-F1, F2-F3 and F4.
Table 4 Multivariate analysis of ALP, bilirubin, albumin
and platelet count for discrimination between F0-F1 and
F2-F3, and F2-F3 and F4 patients
Variables F0-F1/F2-F3 F2-F3/F4
OR (95% CI) P value OR (95% CI) P value
ALP 1.5 (105.13-51.34) < 0.05 1.3 (203.25-124.93) < 0.05
Bilirubin 2.1 (0.399- 0.122) < 0.05 1.4 (0.719- 0.403) < 0.05
Albumin 1.1 (0.126- 0.308) < 0.05 1.3 (0.333- 0.598) < 0.05
Platelet count 1.2 (34.71- 53.35) < 0.05 1.2 (48.63- 75.72) < 0.05
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FCI =

(ALP × Bilirubin)/(Albumin × Platelet count)

The FCI distribution for the patients in the respective
fibrosis stages is represented in Figure 5. The median
values for FCI in F0-F1, F2-F3 and F4 patients were
0.085, 0.32 and 1.9, respectively. FCI significantly corre-
lated with the liver fibrosis stages (Spearman’sr a n kc o r -
relation coefficient, r = 0.818, P< 0.05). The diagnostic
values of F1 to differentiate F0-F1 and F4 patients were
evaluated using the AUROCs (Figure 6). The AUC for
F0-F1 and F4 was 0.932 (CI: 0.895-0.969) and 0.996 (CI:
0.989-1.002), respectively. The cutoff values obtained
from the respective ROC curves were < 0.130 and >
≥1.25 in discriminating F0-F1 and F4 patients, respec-
tively. Table 5 illustrates the diagnostic accuracy of FCI.
Using a cutoff value of < 0.130, FCI had a sensitivity of
81%, PPV of 82% also with a specificity of 87% and NPV
of 82% for the prediction of F0-F1. On the other hand,
at a cutoff value of 1.25 or more, FCI had a sensitivity
of 86%, specificity and PPV of 100% and 98% NPV for
the prediction of cirrhosis (F4).
Discussion
Hepatocellular carcinoma and hepatic cirrhosis are con-
sequences of chronic hepatitis C. The mean infection
time to onset of cirrhosis is approximately 30 years, but
cirrhosis may occur within a range of 10-50 years [20].
Fibrosis and its extension in hepatic tissue is most com-
mon evidence of cirrhosis. Several indexes are available
to predict cirrhosis but no method or score is available
on exclusive basis to diagnose earlier fibrosis stages.
Genotype 3a is the most common one followed by 1a
in Pakistan [[3,21], and [22]] and same was also
observed in this study. Almost, 86% patients had geno-
type 3a while remaining 14% had genotype 1a. A recent
study also reported high prevalence of genotype 3 in
H C Cp a t i e n t si nP a k i s t a n[ 2 3 ] .P a t i e n t sw i t hn o n eo r
initial stage (F0-F1) of fibrosis showed a remarkable dif-
ference of age with advanced stages (F2 and F3) of fibro-
sis and cirrhosis. Most patients with age more than 40
years showed severe fibrosis and cirrhosis. These results
confirmed the previous studies that patients with mild
fibrosis stage were younger than the moderate and
severe disease grade and stage is independent of gender
[24-26].
Our results showed positive correlation of ALT with
A P R Ia n dF I ,a n dn e g a t i v ec o r r e l a t i o nw i t hA A Ra n d
platelet, however, no correlation was established
between ALT levels with disease severity and fibrosis
stages. Our observation is in agreement with previous
reports that serum ALT levels do not accurately predict
the presence of hepatic liver damage [27,28]. Several
authors reported persistently normal ALT levels (< 42
IU/l) in patients with chronic HCV. Almost, 30% of
patients with chronic HCV infection reflect steadily nor-
mal serum ALT levels [29-32], however, in our data
only 10% (n = 16) patients showed normal ALT levels.
Our data showed gradual increase in serum ALP and
bilirubin levels (Table 2) in fibrosis stages when com-
pared to early infection. Both ALP and bilirubin showed
strapping significant correlation with disease progres-
sion. These results lead them to an important predictor
of disease severity. An increased ALP is usually asso-
ciated with liver metastasis, extraheptic bile obstruction,
intraheptic cholestasis, infiltrative liver disease and hepa-
titis [33,34]. According to Lee et al, elevated serum ALP
levels were common in liver abscess patients [35]. High
bilirubin levels are associated with liver metastases and
liver tumor involvement leading to hepatocellular carci-
noma and liver cirrhosis by active or non-active HCV or
HBV [36]. Limited literature is available on the role of
Figure 3 Relationship between fibrosis stages and the ALP,
bilirubin, serum albumin and fibrosis-cirrhosis index (FCI). The
lines through the middle of the boxes represent the median, while
the top and bottom of the boxes are the 25
th and 75
th percentiles.
The error bars represent measurement range (maximum and
minimum values).
Figure 4 Receiver operating characteristic curves for individual
serum markers; ALP, bilirubin, platelet count and serum
albumin for the predication of F0-F1, F2-F3 and F4 fibrosis
stages.
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However, according to Imbert-Bismut et al. [37], biliru-
bin may be used as marker of liver injury, while a
change in ALP levels greater than 120 U/L can be indi-
cative of advanced disease progression [12]. These find-
ings suggest that serum ALP and bilirubin may be used
Table 5 Diagnostic accuracy of the ALP, bilirubin, albumin, platelet count and fibrosis-cirrhosis index (FCI) for the
prediction of F0-F1 stage and hepatic cirrhosis in chronic HCV infected patients (n = 157)
Marker Cutoff Interpretation AUC [95% CI] Spe% Sen% PPV% NPV%
ALP
< 120 F0-F1 (n = 68) F2-F4 (n = 89) 0.829 [0.760-0.897] 69.6 85.2 68.2 86.1
58/10 27/62
> 240 F4 (n = 21) F0-F3 (n = 136) 0.931 [0.882-0.981] 91.9 80.9 60.7 96.9
17/4 11/125
Bilirubin
< 0.95 F0-F1 (n = 68) F2-F4 (n = 89) 0.729 [0.643-0.815] 68.1 85.2 67.4 85.7
58/10 28/60
> 1.5 F4 (n = 21) F0-F3 (n = 136) 0.889 [0.816-0.962] 95.5 66.6 70 94.8
14/7 6/130
Albumin
> 4.1 F0-F1 (n = 68) F2-F4 (n = 89) 0.812 [0.738-0.886] 67.4 100 70.1 100
68/0 29/60
< 3.85 F4 (n = 21) F0-F3 (n = 136) 0.879 [0.796-0.962] 92.6 71.4 60 95.4
15/6 10/126
Platelet count
> 150 F0-F1 (n = 68) F2-F4 (n = 89) 0.935[0.900-0.970] 69.6 98.5 71.2 98.4
67/1 27/62
< 100 F4 (n = 21) F0-F3 (n = 136) 0.990[0.977-1.002] 98.5 80.9 89.4 97.1
17/4 2/134
FCI
< 0.130 F0-F1 (n = 68) F2-F4 (n = 89) 0.932[0.895-0.969] 86.5 80.8 82.1 85.5
55/13 12/77
> 1.25 F4 (n = 21) F0-F3 (n = 136) 0.996[0.989-1.002] 100 85.7 100 97.8
18/3 0/136
Spearman rank correlation coefficient (R-index) for ALP = 0.716, bilirubin = 0.597, albumin = -0.700, platelet count = -0.817 and FCI = 0.818.
Figure 5 Box plot of fibrosis-cirrhosis index (FCI) for each
fibrosis stage. The horizontal line inside each box represents the
median, while the top and bottom of boxes represent the 25
th and
75
th percentiles, respectively. Vertical lines from the ends of the box
encompass the extreme data points.
Figure 6 Receiver operating characteristic curves generated by
the fibrosis-cirrhosis index (FCI) to discriminate fibrosis stages
F0-F1 and F4. FCI showed maximum AUC for prediction of F4
(cirrhosis).
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Page 7 of 10as serum markers to assess the disease progression and
fibrosis stages in chronic HCV patients.
Many studies supported that platelet count alone may
be clinically valuable as a non-invasive serum marker
for liver fibrosis and cirrhosis [38,39]. Platelets not only
predict fibrosis but also correlate with fibrotic stages
[40-42]. Lackner et al,[ 4 3 ]s h o w e dh i g hA U R O Co f
0.89 for predicting cirrhosis at platelet value < 150 ×
10
9/L and AUROC of 0.71 for non-cirrhotic patients at
a cutoff value > 150 × 10
9/L. Our data is also in accor-
dance with these results as platelet count showed high
AUROC (≥ 0.900) to differentiate different liver fibrosis
stages as given in Table 5 and Figure 4. In our study,
platelet count was significantly low in cirrhotic patients.
At a cutoff value of platelet, < 100 × 10
9/L has an
AUROC of 0.990 for prediction of cirrhosis with 81%
sensitivity and 98% specificity. Ginnani et al,r e p o r t e d
platelet < 130 × 10
9/L for prediction of cirrhosis in
HCV patients with 91.1% sensitivity, 88.3% specificity,
PPV 81.2% and NPV 94.7% [44].
We also examined the ability of AAR, APRI, FIB-4
and F-Index for staging liver fibrosis and to differentiate
them from cirrhosis. Giannini et al,r e p o r t e dah i g h
diagnostic accuracy of AAR > 1.16 with 81.3% sensitivity
and 55.3% specificity for the prediction of cirrhosis [44].
However, AAR was not able to differentiate among liver
fibrosis stages in our sample data. At value of > 1.0,
AAR has 43% sensitivity and 70% specificity for differen-
tiating fibrosis from cirrhosis (Table 3). This poor per-
formance of AAR is similar to that reported by Lackner
et al [43].
We observed comparatively high APRI (1.24 ± 0.8)
and FIB-4 (1.76 ± 1.35) values in F0-F1 patients. The
group F0-F1 contains two subgroups, patients with no
fibrosis (F0) and with minimal fibrosis (F1). The mean
value of APRI and FIB-4 in F0 was 1.04 and 1.21, and in
F1 1.39 and 2.17, respectively (Table 2). It is reported
that APRI < 0.42 predict mild fibrosis and APRI > 1.2,
significant fibrosis in HCV patients with 90% NPV for
absence of fibrosis and 91% PPV for fibrosis presence
[45-47]. Our results showed that APRI > 1.5 could pre-
dict fibrosis with 55% sensitivity, 67% specificity. More-
over, by using same cutoff value of APRI > 1.5 in a
recent study by Macias et al [48], found that it has 28%
sensitivity, 92% specificity, 79% PPV and 55% NPV for
predicting significant fibrosis, and for absence of fibrosis
APRI < 0.5 has 78%, 44%, 59% and 66% sensitivity, spe-
cificity, PPV and NPV, respectively.
FIB-4 was developed by Sterling et al in 2006 for diag-
n o s i so ff i b r o s i sa n dc i r r h o sis in HIV/HCV co-infected
patients. We examined this index only for HCV infected
patients. A cutoff value of < 1.45 FIB-4 has a NPV for
the exclusion of advanced fibrosis of 90%, while a cutoff
value > 3.25 has a PPV for the diagnosis of extended
fibrosis of 65% [49]. At a cutoff value of < 1.45, Vallet-
Pichard observed a high NPV of 94.7% with a sensitivity
of 74.3% to exclude severe fibrosis. Where as, for con-
firming the presence of advanced fibrosis at cutoff value
> 3.25, FIB-4 had a PPV of 82.1% with specificity of
98.2% [18]. Our results are not in agreement with Ster-
ling or Vallet-Pichard, as we observed a low NPV (70%)
for excluding significant fibrosis, however, we detected a
PPV of 83% with specificity of 45% for the presence of
advanced fibrosis at cutoff value > 3.25. Trang et al
[50], proposed new cutoff values of FIB-4 ≤ 1.39 for F0-
F1 and ≥2.05 for F2-F4 stage in HCV/HIV co infected
patients. At these cutoffs, we observed sensitivity 52%,
specificity 76%, PPV 63% and NPV 68% for no/minimal
fibrosis and 60%, 63%, 68% and 55% for advanced fibro-
sis, respectively. Although, we observed low statistical
values, our results were in accordance to advance stage
prediction. The cut off values proposed by Trang et al
better predict fibrosis stages in co infected patients and
we applied on only HCV infected patients.
Fibrosis index (FI) showed high sensitivity, specificity,
PPV, NPV and AUROC for discriminating different
fibrosis stages. Ohta developed this simple index in
2006. At cutoff value < 2.1 FI showed sensitivity and
specificity for predicting F0-1 stage 66.8% and 78.8% in
initial cohort and 68.5% and 63.6% in validation cohort,
respectively [17]. At same cutoff, our data showed 100%
sensitivity and 58.4% specificity with AUROC 0.939 for
the prediction of none/minimal fibrosis. While for pre-
dicting cirrhosis in HCV patients, FI value > 3.30 has
sensitivity and specificity 67.7% and 75% in initial
cohort, and 70.8% and 81% in validation cohort, respec-
tively. However, at this value we observed 33% sensitiv-
ity and 100% specificity for predicting cirrhosis (Table
3). We proposed that a new cutoff value of FI > 2.5 can
better predict cirrhosis with 95.2% sensitivity and 94%
specificity.
The readily available indexes are associated with
some limitations like population discrepancy, not able
to distinguish all fibrosis stages individually or some
primarily developed for co-infected patients. So there
is a need to develop a new index that can distinguish
minimal fibrosis (F0-F1) from significant (F2-F4) and
advanced (F2-F3) from cirrhosis (F4). While consider-
ing substantial relationship of routinely applied tests;
serum ALP, ALT, AST, Hb level, bilirubin, albumin
and platelet count with liver fibrosis stages, we found
that four serum markers ALP, bilirubin, albumin and
platelet count have high potential to differentiate dif-
ferent fibrosis stages and cirrhosis at given cutoff
values (Table 5 and Figure 4). We also observed that
combination of these serum markers could better dif-
ferentiate among fibrosis stages with high sensitivity,
specificity, PPV and NPV.
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Page 8 of 10Our newly derived index FCI showed better perfor-
mance for discriminating between fibrosis stages as
c o m p a r e dt oA A R ,A P R Ia n dF I .I ni n i t i a lc o h o r t ,t h e
AUROC for predicting F0-F1 stage for FCI was 0.932
when compared to recently used non-invasive serum
markers like AAR (AUROC = 0.570) [15], APRI
(AUROC = 0.880) [16], FI (AUROC = 0.741) [17], FIB-4
(AUROC = 0.793) [18], Forn’s index (AUROC = 0.860)
[51], and Fibrotest (AUROC = 0.870) [52]. Moreover,
FCI (AUROC = 0.996) showed better performance for
predicting cirrhosis than above mentioned serum
indexes. Although in our study, platelet count showed
high AUROC to predict fibrosis stages, systematic litera-
ture reviews consistently shown that panel of fibrosis
markers are more accurate than single marker. Combi-
nation of two or more serum markers in a mathematical
algorithm provide better chance of predicting phase of
disease progression instead of individual one [37,53-57].
This analysis showed that FCI has tendency to reflect
respective fibrosis stages from no/minimal to cirrhosis
with great accuracy (Table 5, Figure 5 and 6). However,
several studies are needed to verify these results. Sec-
ondly, because of poverty and fear of biopsy, we are not
yet able to get enough patient data for verification of
our FCI results in new cohort.
Conclusions
For Pakistani population the mostly used markers were
failed to predict fibrosis stages in patients with HCV
with accuracy. This study concluded that a simple index
(FCI) containing ALP, bilirubin, albumin and platelet
count may accurately classify different fibrosis stages
from none to cirrhosis. Future studies are required to
assess the applicability of this fibrosis-cirrhosis index
within different populations and in patients with HBV
or other fatty liver diseases.
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